TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00869596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to fluticasone
Description: Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Lipopolysaccharide (LPS)
Description: 20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Lipopolysaccharide (LPS)
Description: 20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Lipopolysaccharide (LPS)
Description: 20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: albuterol
Description: Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: albuterol
Description: Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: albuterol
Description: Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
Study: NCT01725399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT00512668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT05743855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Nutritional Supplement + Chiropract sessions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Chiropractic sessions
Study: NCT02097277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Matching with BMS-986036)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with BMS-986036)
Study: NCT01381510

Intervention type: DRUG
Intervention: 5-alpha Reductase Inhibitor (5ARI)
Description: A 5ARI: Either dutasteride or finisteride

Intervention type: DRUG
Intervention: 5-alpha Reductase Inhibitor (5ARI)
Description: A 5ARI: Either dutasteride or finisteride
Study: NCT02841735

Intervention type: DEVICE
Intervention: Smartphone breathalyzer device/app use
Description: Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.

Intervention type: DEVICE
Intervention: BAC estimator app use
Description: Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.

Intervention type: DEVICE
Intervention: Text messaging procedure
Description: Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
Study: NCT03006120

Intervention type: PROCEDURE
Intervention: Retroperitoneal hematoma due to cardiac catheterization

Intervention type: PROCEDURE
Intervention: Retroperitoneal hematoma due to cardiac catheterization

Intervention type: PROCEDURE
Intervention: Retroperitoneal hematoma due to cardiac catheterization
Study: NCT01533220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naphazoline hydrocloride
Description: 02 drops into each nostril, 04 times a day for 03 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naphazoline hydrocloride + Pheniramine Maleate + Panthenol
Description: 02 drops into each nostril each 12 hours for 03 days
Study: NCT03320369

Intervention type: OTHER
Group type: OTHER
Intervention: Elemental Diet Therapy
Description: Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
Study: NCT01055912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
Study: NCT04488185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg administered s.c. (2 single-use prefilled syringes of 150 mg/mL), on Days 1, 8, 15, 22, 29, 57, 85.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered s.c. (2 single-use prefilled 1 mL syringes) on Days 1, 8, 15, 22, 29, 57, 85.
Study: NCT02174172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Description: Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2a
Description: Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2a
Description: Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
Study: NCT03414632

Intervention type: DRUG
Group type: OTHER
Intervention: 99mTc-PYP
Description: Radioisotope used in the SPECT/CT imaging
Study: NCT03291015

Intervention type: DEVICE
Group type: OTHER
Intervention: radiographic
Description: using plain x ray to determind the treatment plan

Intervention type: DEVICE
Group type: OTHER
Intervention: arthroscopy
Description: using wrist arthroscopy to determind the treatment plan
Study: NCT00580398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
Study: NCT04697706

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moonstone
Description: Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period.
Study: NCT00932854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS
Description: Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
Study: NCT01771913

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: centrifuged fat graft
Description: fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: ADSCs enriched fat graft
Description: fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
Study: NCT03852576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP/QRH dimer
Description: KSP-QRH-E3-IRDye800 (Peptide 919288G)
Study: NCT01407419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Acceleration
Description: Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Assessment
Description: Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
Study: NCT03847077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPad counseling
Description: Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Counseling
Description: Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
Study: NCT01597232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion trigger based on WCPTS
Description: Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of hemoglobin level more than 10g/dL
Description: The patient's hemoglobin level is maintained more than 10g/dL perioperatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion trigger based on experience
Description: Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
Study: NCT01834261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon Nasal Spray, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon Nasal Spray, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon Placebo Formulation, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon Placebo Formulation, 40IU
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Study: NCT02536794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B7H1 Monoclonal Antibody MEDI4736
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT04360720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Monotherapy
Description: All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone until the end of the study, at Month 12.
Study: NCT04106037

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT00026338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: 150 mg po daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
Study: NCT03609840

Intervention type: DRUG
Intervention: Thiotepa
Description: Given IV
Study: NCT00607594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
Study: NCT03155477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and C. Xanthorrhiza
Description: Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol and placebo
Description: Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
Study: NCT04003571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality with Functional Electrical Stimulation group
Description: Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
Study: NCT02646059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone
Description: Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
Study: NCT03268187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: The skin conductance of the patient is measured and fed back to the patient via screen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: The skin conductance of the patient is measured and fed back to the patient via screen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Alert Training
Description: Self-Alert Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Relaxation Training
Study: NCT02984137

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: testing, evaluation, sampling
Description: neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: testing, evaluation, sampling
Description: neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: testing, evaluation, sampling
Description: neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
Study: NCT02007772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nHF
Description: nasal high-flow is used over a period of 6 weeks (outpatient)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nHF
Description: nasal high-flow is used over a period of 6 weeks (outpatient)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP
Description: BiPAP is used over a period of 6 weeks (outpatient)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: BiPAP is used over a period of 6 weeks (outpatient)
Study: NCT03454958

Intervention type: OTHER
Intervention: Measurements of body composition
Description: Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer \& skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.